A phase 1/2 study investigated olutasidenib (FT-2102), a mutant IDH1 inhibitor, in patients with advanced solid tumors and gliomas, either as monotherapy or combined with azacitidine for glioma treatment. This evidence concerns the gene IDH1 and glioma.